Hemp oil for ALS and Alzheimer's disease

Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by muscle spasticity, rapidly progressive weakness, muscle wasting, dysphagia, aphasia and respiratory failure. Dysregulation of the inflammatory response and GABA imbalance are associated with the development of the disease.

Many of the processes in which cannabinoids are involved occur because they bind to CB receptors and inhibit the release of pro-inflammatory cytokines and chemokines to eliminate the inflammatory response, as shown by preclinical models.

Cannabinoids also have a significant impact on inhibiting oxidative and nitrosation stress (combined damage resulting from reactive oxygen and nitrogen species), modulating the expression of nitric oxide synthase and limiting the production of reactive forms (nitrogen - RNS and oxygen - ROS).

In addition, phytocannabinoids were found to reduce excitotoxicity by inhibiting the release of glutamate. Hemp oil enhances the action of an inhibitory neurotransmitter: gamma-aminobutyric acid (GABA). Recent in vivo studies support these observations and prove that CBD hemp oils may have benefits as neuroprotective factors in ALS.

Referring to a similar issue, treatment with CBD hemp oil (CBD, a non-intoxicating cannabinoid) due to its affinity for CB1 receptors seems to significantly delay the onset of the disease.

Alzheimer's disease

Alzheimer's disease is a progressive neurodegenerative disease that affects neurons, leading to loss of memory, language skills and cognitive functions, as well as changes in mood and behavior. The death of neurons causes a progressive deterioration of neurological symptoms.

In the initial period, there is damage to the nerve cells of the hippocampus, which causes a deterioration in short-term memory. With the progression of the disease and damage to the cerebral cortex, there is a deterioration in language skills and impaired assessment ability.

Alzheimer's disease is considered to be associated with clinical endocannabinoid deficiency ,, CECD, and CBD hemp oil has been proposed as an antioxidant factor for the treatment of neurodegenerative diseases. CBD has been shown to stimulate PPAR-gamma receptors, which destroy amyloid plaques, which play a fundamental role in the development of Alzheimer's disease.

Further research and the U.S. patent number 6630507 support the use of CBD as a preventive agent against Alzheimer's disease, highlighting the anti-inflammatory and neuroprotective properties of CBD.

The above results suggest that CBD could be a promising tool in the prevention and treatment of Alzheimer's disease.

For typical neurological diseases, decarboxylated CBD oil with the highest bioavailability is recommended.